Budowa i zastosowanie wybranych glikozoaminoglikanow

• Autorzy: Zeyland J , Lipinski D. , Juzwa W. , Plawski A. , Slomski R.
• Języki publikacji: PL

Abstrakty

EN

Proteoglycans can be found in the extracellular matrix of most tissues. They play the role of receptors, take part in cellular adhesion and also interactions between cells. Proteoglycans consist of proteins with one or more covalently bonded glycosaminoglycans. There are seven different types of glycosaminoglycans: hyaluronic acid, heparin and sulphates of chondroitin, keratan I and II, heparin and dermatan. Hyaluronic acid and chondroitin sulphate appear in synovial fluid where they take part in binding water, preventing mechanical stress and increasing elasticity. Keratan sulphate and chondroitin sulphate are used as potential markers of osteoarthritis. Osteoarthritis is a type of arthritis that is caused by the breakdown and eventual loss of the cartilage of one or more joints. Cartilage is a protein substance that serves as a cushion between the bones of the joints. Dermatan sulphate is responsible for the individual resistance to inflammation and pathogens. Understanding the mechanisms of interactions between glycosaminoglycans and pathogens will help to develop more effective vaccinations. The perfect functioning of glycosaminoglycans depends on the efficient activity of both synthesising and degrading enzymes. Even small dysfunctions cause major diseases and disorders.

Słowa kluczowe

PL

kwas hialuronowy; zastosowanie; siarczan keratanu II; heparyna; budowa; proteoglikany; siarczan heparanu; siarczan dermatanu; glikozoaminoglikany; siarczan keratanu I; siarczan chondroityny

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2006
• Tom: 62
• Numer: 02
• Strony: 139-144
• Opis fizyczny: s.139-144,bibliogr.

Twórcy

autor

Zeyland J

• Akademia Rolnicza, ul. Wolynska 32, 60-637 Poznan

autor

Lipinski D.

autor

Juzwa W.

autor

Plawski A.

autor

Slomski R.

Bibliografia

• 1.Amiel D., Toyoguchi T., Kobayashi K., Bowden K., Amiel M. E., Healey R. M.: Long-term effect of sodium hyaluronate (Hyalgan) on osteoarthritis progression in a rabbit model. Osteoarthr. Cartilage 2003, 11, 636-643.
• 2.Belcher C., Yaqub R., Fawthrop F., Bayliss M., Doherty M.: Synovial fluid chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in arthritic and normal knees. Ann. Rheum. Dis. 1997, 56, 299-307.
• 3.Borawski J., Naumnik B., Mysliwiec M.: Hepatocyte growth factor: a possible mediator of heparin-induced osteoporosis? Clin. Appl. Thromb. Hemost. 2003, 9, 171-172.
• 4.Brown E. L., Wooten R. M., Johnson B. J., Iozzo R. V., Smith A., Dolan M. C., Guo B. P., Weis J. J., Hook M.: Resistance to Lyme disease in decorin-deficient mice. J. Clin. Invest. 2001, 107, 845-852.
• 5.Chauvin K., Bratton C., Parkins C.: Healing large tympanic membrane perforations using hyaluronic acid, basic fibroblast growth factor, and epidermal growth factor. Otolaryngol. Head Neck Surg. 1999, 121, 43-47.
• 6.Cywes C., Wessels M. R.: Group A Streptococcus tissue invasion by CD44- -mediated cell signalling. Nature 2001, 414, 648-652.
• 7.Echtermeyer F., Streit M., Wilcox-Adelman S., Saoncella S., Denhez F., Detmar M., Goetinck P.: Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J. Clin. Invest. 2001, 107, R9-R14.
• 8.Funderburgh J. L.: Keratan sulfate biosynthesis. IUBMB Life 2002, 54, 187-194.
• 9.Grobe K., Ledin J., Ringvall M., Holmborn K., Forsberg E., Esko J. D., Kjellen L.: Heparan sulfate and development: differential roles of the N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes. Biochim. Biophys. Acta 2002, 19, 209-215.
• 10.Harmon B. G., Glisson J. R., Latimer K. S., Steffens W. L., Nunnally J. C.: Resistance of Pasteurella multocida A:3,4 to phagocytosis by turkey macrophages and heterophils. Am. J. Vet. Res. 1991, 52, 1507-1511.
• 11.Humphries D. E., Wong G. W., Friend D. S., Gurish M. F., Qiu W. T., Hung C., Sharpe A. H., Stevens R. L.: Heparin is essential for the storage of specific granule proteases in mast cells. Nature 1999, 400, 769-772.
• 12.Innes J. F., Sharif M., Barr A. R. S.: Changes in concentrations of biochemical markers of osteoarthritis following surgical repair of ruptured cranial cruciate ligaments in dogs. Am. J. Vet. Res. 1999, 60, 1164-1168.
• 13.Klaassen C. D., Boles J. W.: Sulfation and sulfotransferases 5: the importance of 3'-phosphoadenosine 5’-phosphosulfate (PAPS) in the regulation of sulfation. FASEB J 1997, 11, 404-418.
• 14.Kovanen P. T., Pentikainen M. O.: Decorin links low-density lipoproteins (LDL) to collagen: a novel mechanism for retention of LDL in the atherosclerotic plaque. Trends Cardiovasc. Med. 1999, 9, 86-91.
• 15.Lewis S., Crossman M., Flannelly J., Belcher C., Doherty M., Bayliss M. T., Mason R. M.: Chondroitin sulphation patterns in synovial fluid in osteoarthritis subsets. Ann. Rheum. Dis. 1999, 58, 441-445.
• 16.Liu J., Thorp S. C.: Cell surface heparan sulfate and its roles in assisting viral infections. Med. Res. Rev. 2002, 22, 1-25.
• 17.Lohmander L. S.: Markers of cartilage metabolism in arthrosis. Acta Orthop. Scand. 1991, 62, 623-632.
• 18.Manna F., Dentini M., Desideri P., De Pita O., Mortilla E., Maras B.: Comparative chemical evaluation of two commercially available derivatives of hyaluronic acid (hylaform from rooster combs and restylane from streptococcus) used for soft tissue augmentation. J. Eur. Acad. Dermatol. Venerol. 1999, 13, 183-192.
• 19.Michanetzis G., Katsala N., Missirlis Y.: Comparison of haemocompatibility improvement of four polymeric biomaterials by two heparinization techniques. Biomaterials 2003, 24, 677-688.
• 20.Mousa S. A., Fareed J.: Overview: from heparin to low molecular weight heparin: beyond anticoagulation. Curr Opin Investig Drugs 2001, 2, 1077- -1080.
• 21.Myers S. L.: Synovial fluid markers in osteoarthritis. Rheum. Dis. Clin. North Am. 1999, 25, 433-449.
• 22.Ninomiya T., Sugiura N., Tawada A., Sugimoto K., Watanabe H.: Molecular cloning and characterization of chondroitin polymerase from Escherichia coli strain K4. J. Biol. Chem. 2002, 277, 21567-21575.
• 23.Nizet V., Ohtake T., Lauth X., Trowbridge J., Rudisill J., Dorschner R. A., Pestonjama V., Piraino J., Huttner K., Gallo R. L.: Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001, 414, 454-457.
• 24.Orloff L. A., Glenn M. G., Domb A. J., Esclamado R. A.: Prevention of venous thrombosis in microvascular surgery by transmural release of heparin from a polyanhydride polymer. Surgery 1995, 117, 554-559.
• 25.Penc S. F., Pomahac B., Eriksson E., Detmar M., Gallo R. L.: Dermatan sulfate activates nuclear factor-kappab and induces endothelial and circulating intercellular adhesion molecule-1. J. Clin. Invest. 1999, 103, 1329-1335.
• 26.Penc S. F., Pomahac B., Winkler T., Dorschner R. A., Eriksson E., Gallo R. L.: Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function. J. Biol. Chem. 1998, 263, 28116-28121.
• 27.Raats C. J., Van Den Born J., Berden J. H.: Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int. 2000, 57, 385-400.
• 28.Rabenstein D. L.: Heparin and heparan sulfate: structure and function. Nat. Prod. Rep. 2002, 19, 312-331.
• 29.Roberts J. A.: Tropism in bacterial infections: urinary tract infections. J. Urol. 1996, 156, 1552-1559.
• 30.Rorvik A. M., Grondahl M.: Markers of osteoarthritis: a review of the literature. Vet. Surg. 1995, 24, 255-262.